Glenmark Pharmaceuticals Inc., USA has recalled 16,944 bottles of Ranolazine (ranolazine) Extended-Release Tablets 500mg, a medication used to treat chronic chest pain. The recall was initiated because the tablets failed dissolution specifications, meaning the drug may not dissolve at the required rate in the body. This recall affects 60-count bottles of the prescription medication distributed throughout the United States.
If the medication fails to dissolve as intended, the patient may receive too much or too little of the drug, which can lead to ineffective management of heart-related chest pain. No reports of injuries or adverse events were mentioned in the recall data.
You have 2 options:
Recall Number: D-0092-2024. Manufactured by Glenmark Pharmaceuticals Limited in India.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.